Axonal Transport Dysfunction Comparison Across Neurodegenerative Diseases

Axonal Transport Dysfunction in Neurodegenerative Diseases

> A cross-disease comparison of axonal transport impairment mechanisms, molecular drivers, and therapeutic implications

Overview

Axonal transport is a critical cellular process that maintains neuronal function by moving organelles, proteins, and signaling molecules between the cell body and synaptic terminals along microtubules. This bidirectional transport system relies on motor proteins (kinesins for anterograde, dyneins for retrograde) and is essential for synaptic maintenance, mitochondrial distribution, and cargo delivery. All major neurodegenerative diseases exhibit some degree of axonal transport dysfunction, which contributes to axonal degeneration and neuronal death. This page compares axonal transport impairment across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD).

Comparison Matrix

Axonal Transport Dysfunction in Neurodegenerative Diseases

> A cross-disease comparison of axonal transport impairment mechanisms, molecular drivers, and therapeutic implications

Overview

Axonal transport is a critical cellular process that maintains neuronal function by moving organelles, proteins, and signaling molecules between the cell body and synaptic terminals along microtubules. This bidirectional transport system relies on motor proteins (kinesins for anterograde, dyneins for retrograde) and is essential for synaptic maintenance, mitochondrial distribution, and cargo delivery. All major neurodegenerative diseases exhibit some degree of axonal transport dysfunction, which contributes to axonal degeneration and neuronal death. This page compares axonal transport impairment across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD).

Comparison Matrix

| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|---------------------|---------------------|-----|-----|----------------------|
| Primary Transport Defect | Tau-mediated, Aβ-induced | α-Synuclein-mediated, mitochondrial | TDP-43, dynein/dynactin mutations | Tau or TDP-43 dependent | Mutant huntingtin blocks motors |
| Kinesin-1 (KIF5) Function | Severely impaired | Moderately impaired | Moderately impaired (KIF5A mutations) | Tau-dependent impairment | Severely impaired |
| Dynein Function | Moderately impaired | Moderately impaired | Severely impaired (mutations) | Variable | Impaired |
| Dynactin Function | Moderately impaired | Moderately impaired | Severely impaired (DCTN1) | Mild | Severely impaired |
| Mitochondrial Transport | Severely impaired | Severely impaired | Impaired | Variable | Severely impaired |
| Synaptic Vesicle Transport | Impaired | Impaired | Impaired | Variable | Impaired |
| Microtubule Integrity | Tau-mediated destabilization | LRRK2-mediated dysfunction | Variable | Tau-mediated destabilization | Impaired |
| Motor Protein Mutations | APOE ε4 modifies transport | LRRK2, DCTN1 | KIF5A, DYNC1H1, DCTN1 | MAPT, GRN | HTT (direct effect) |
| Therapeutic Target | Microtubule stabilizers | LRRK2 inhibitors | Transport enhancers | Depends on subtype | Transport enhancers |
| Evidence Level | Strong | Strong | Moderate-Strong | Moderate | Moderate |

Molecular Motor Systems

Overview of Axonal Transport

Axonal transport is a critical cellular process that maintains neuronal function by moving organelles, proteins, and signaling molecules between the cell body and synaptic terminals along microtubules. This bidirectional transport system relies on motor proteins (kinesins for anterograde, dyneins for retrograde) and is essential for synaptic maintenance, mitochondrial distribution, and cargo delivery. All major neurodegenerative diseases exhibit some degree of axonal transport dysfunction, which contributes to axonal degeneration and neuronal death. This page compares axonal transport impairment across Alzheimer's Disease (AD), Parkinson's Disease (PD), Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), and Huntington's Disease (HD).

The molecular machinery of axonal transport consists of three major components: microtubules as the track, motor proteins as the engines, and adaptor proteins that link cargo to motors. Microtubules are polarized structures with plus ends pointing toward the synapse and minus ends toward the cell body. This polarity determines the direction of transport: kinesins move toward the plus ends (anterograde), while dyneins move toward the minus ends (retrograde).

Kinesins constitute a large family of motor proteins with over 45 members in humans. Kinesin-1 (KIF5) is the primary anterograde motor in neurons, consisting of two heavy chains (KHC) that contain the motor domains and two light chains (KLC) that bind cargo. Kinesin-1 can transport synaptic vesicles, mitochondria, membrane organelles, and signaling complexes. The motor domain of kinesin binds to microtubules and uses ATP hydrolysis to generate force, moving in discrete steps of approximately 8 nm along the microtubule lattice. The processivity of kinesin-1 (ability to take many steps before detaching) is mediated by its coiled-coil stalk that holds the two heads in a processive conformation [1](https://pubmed.ncbi.nlm.nih.gov/23418699/).

Dynein is a large complex consisting of the heavy chain (containing the motor domain), intermediate chain, light intermediate chain, and several light chains. The dynein complex requires dynactin as a cofactor for full activity and processivity. Dynactin is a multisubunit complex that enhances dynein processivity and links dynein to cargo. The DCTN1 gene encoding the p150Glued subunit of dynactin is mutated in some cases of ALS and Perry syndrome, causing progressive parkinsonism [2](https://pubmed.ncbi.nlm.nih.gov/25877247/).

Adaptor proteins that link cargo to motors include JIP1, JIP2, JIP3 (JNK-interacting proteins) for kinesin-1, and Rab proteins for organelle transport. These adaptors provide specificity to transport and allow regulation by signaling pathways. For example, JIP1 links kinesin-1 to the MAPK signaling pathway and is phosphorylated by various kinases, providing a mechanism for regulation of transport by neuronal activity and stress [3](https://pubmed.ncbi.nlm.nih.gov/19015241/).

Disease-Specific Motor Dysfunction

| Motor | AD | PD | ALS | FTD | HD |
|-------|-----|-----|------|------|-----|
| Kinesin-1 (KIF5) | ↓↓ Activity | ↓↓ Inhibition by α-syn | ↓ Normal (KIF5A mutations) | ↓ Tau-mediated | ↓↓ Function |
| Kinesin-2 (KIF3) | ↓ | ↓ | - | - | ↓ |
| Kinesin-3 (KIF1A) | - | ↓ | ↓ (ALS mutations) | - | - |
| Dynein (DYNC1H1) | ↓ | ↓ | ↓↓ Mutations | Variable | ↓ |
| Dynactin (DCTN1) | ↓ | ↓ | ↓↓ Mutations | - | ↓↓ |

Motor Protein Structure and Function

The kinesin-1 motor domain (approximately 340 amino acids) contains the microtubule-binding site and ATP-binding pocket. The binding and hydrolysis of ATP drives conformational changes that produce stepping motion. Kinesin-1 can transport cargo at velocities of 0.5-1 μm/s, sufficient to move cargo across the length of an axon in hours. The processivity of kinesin-1 is enhanced by its "walking" motion, where one head is always bound to the microtubule [4](https://pubmed.ncbi.nlm.nih.gov/25849938/).

Dynein is structurally and mechanistically distinct from kinesins. The dynein heavy chain contains six AAA+ domains (AAA1-6), of which AAA1 is the primary motor domain that binds microtubules and hydrolyzes ATP. The mechanical stroke of dynein involves a coordinated conformational change across these domains. Dynein processivity is much lower than kinesin-1, but this is compensated by the dynein-dynactin complex, which increases processivity by approximately 10-fold [5](https://pubmed.ncbi.nlm.nih.gov/26232220/).

The regulation of axonal transport is complex and involves multiple mechanisms:

• Phosphorylation: Kinases such as GSK3β, CDK5, and MAPK can phosphorylate motor proteins and alter their activity
• Microtubule post-translational modifications: Acetylation, detyrosination, and polyglutamylation affect motor protein binding and processivity
• Motor protein associations: Accessory proteins can activate or inhibit motor function
• Cargo modifications: Ubiquitination and other post-translational changes can affect adaptor binding

Molecular Mechanisms of Axonal Transport Dysfunction

Microtubule Dysfunction and Motor Protein Regulation

Microtubules serve as the track for axonal transport, and their integrity is crucial for proper function. In neurodegenerative diseases, microtubules are damaged through multiple mechanisms, leading to transport impairment. The tubulin code—the collection of post-translational modifications on tubulin—regulates motor protein binding and processivity, and alterations in this code contribute to transport dysfunction.

Tubulin Post-Translational Modifications

• Acetylation: Stabilized microtubules are acetylated on lysine 40 of α-tubulin. HDAC6 (histone deacetylase 6) removes this acetyl group, promoting microtubule destabilization. In AD, PD, and HD, HDAC6 activity is elevated, leading to reduced microtubule acetylation and impaired transport [6](https://pubmed.ncbi.nlm.nih.gov/22906088/).
• Detyrosination: Removal of the C-terminal tyrosine from α-tubulin marks stable microtubules. Detyrosinated microtubules are preferentially used for long-range transport, and their reduction in disease affects transport efficiency.
• Polyglutamylation: This modification enhances binding of dynein to microtubules and is altered in several neurodegenerative conditions [7](https://pubmed.ncbi.nlm.nih.gov/25849456/).

• Spastin and katanin are microtubule-severing enzymes whose activity is increased in several neurodegenerative conditions
• In AD, tau hyperphosphorylation leads to microtubule instability and increased severing
• In ALS, spastin mutations cause hereditary spastic paraplegia, demonstrating the importance of microtubule integrity

Energy Metabolism and Transport

Axonal transport is an energy-intensive process that requires ATP produced primarily by mitochondria. Transport defects often accompany mitochondrial dysfunction, creating a vicious cycle where impaired energy production further compromises transport.

ATP Requirements for Transport

• Kinesin-1 consumes approximately 1 ATP per 8-nm step, with transport of a single vesicle requiring thousands of ATP molecules
• The highly energy-demanding nature of transport makes neurons particularly vulnerable to mitochondrial dysfunction
• Mitochondrial density is highest at synapses and nodes of Ranvier, reflecting the high local energy demand [8](https://pubmed.ncbi.nlm.nih.gov/26231742/)

• Mitochondria are actively transported to regions of high energy demand, and this positioning is disrupted in neurodegenerative diseases
• The Miro1 protein connects mitochondria to motors; PINK1 phosphorylates Miro1 to trigger mitophagy, but this pathway is impaired in PD
• Mutations in PINK1 and Parkin disrupt mitochondrial quality control and positioning [9](https://pubmed.ncbi.nlm.nih.gov/23695683/)

Cargo-Specific Transport Defects

Different cargo types use distinct motor proteins and adaptor complexes, allowing for specialized regulation. Disease processes affect specific cargo types preferentially.

Synaptic Vesicle Transport

• Synaptic vesicles are transported from the cell body to the synapse by kinesin-3 family members (KIF1A, KIF1B)
• Synapsin I phosphorylation regulates vesicle release and transport; Aβ impairs this process in AD
• In PD, α-synuclein oligomers bind to synaptic vesicles and disrupt their transport [10](https://pubmed.ncbi.nlm.nih.gov/26085256/)

• Mitochondrial transport is mediated by Milton (KIF5 adaptor) and Miro1/2
• Miro1 senses calcium and mitochondrial membrane potential, halting transport when mitochondria are damaged
• In all major neurodegenerative diseases, mitochondrial transport is severely impaired [11](https://pubmed.ncbi.nlm.nih.gov/25058852/)

• Lysosomes and autophagosomes are transported by both kinesin and dynein motors
• Impaired lysosomal transport contributes to the accumulation of undegraded material in neurodegenerative diseases
• Autophagosome transport is particularly affected when autophagy is induced, as the fusion of autophagosomes with lysosomes requires proper transport to the cell body [12](https://pubmed.ncbi.nlm.nih.gov/25323781/)

Disease-Specific Mechanisms Deep Dive

Alzheimer's Disease

Axonal transport in AD is severely impaired through multiple mechanisms. Tau protein, when hyperphosphorylated, dissociates from microtubules and binds to kinesin motors, disrupting their ability to transport cargo. This leads to reduced delivery of synaptic proteins to nerve terminals and accumulation of cargo in the cell body. Aβ oligomers directly impair mitochondrial transport, causing energy deficits at synapses. Dynein function is also compromised, affecting retrograde transport of signaling endosomes and lysosomes. The combined defects result in synaptic degeneration that correlates with cognitive decline. APOE ε4 carriers show additional impairment of axonal transport through lipid metabolism defects.

Tau-Mediated Disruption

The tau protein plays a critical role in microtubule stability in neurons. In AD, tau becomes hyperphosphorylated at over 40 potential phosphorylation sites, leading to its detachment from microtubules. This has two major consequences for transport: first, microtubules become less stable and more susceptible to damage; second, free tau can directly interfere with motor protein function.

Hyperphosphorylated tau loses microtubule binding capacity and may actually compete with kinesin for microtubule binding sites [13](https://pubmed.ncbi.nlm.nih.gov/18328508/). Tau oligomers and fibrils ("neurofibrillary tangles") physically block transport by occupying space on microtubules and trapping motor proteins. Importantly, transport deficits appear early in disease progression, preceding clinical symptoms by decades and correlating with the spread of tau pathology through connected brain regions [14](https://pubmed.ncbi.nlm.nih.gov/22113675/).

The impact of tau on transport is mediated through several mechanisms:

• Direct interaction of tau with kinesin light chains, reducing cargo binding
• Tau-induced microtubule destabilization reducing motor processivity
• Tau aggregates trapping motors and blocking the track
• Tau-mediated activation of kinases (GSK3β, CDK5) that phosphorylate motor proteins

Aβ oligomers directly impair kinesin function through multiple pathways. Aβ reduces synapsin I phosphorylation, affecting synaptic vesicle transport and cycling [15](https://pubmed.ncbi.nlm.nih.gov/19450654/). Aβ oligomers bind to the nerve terminal and cause local energy deficits by impairing mitochondrial function and transport.

Mitochondrial transport is particularly sensitive to Aβ toxicity. Aβ oligomers bind directly to mitochondria and impair their transport, contributing to energy deficits at the synapse. This creates a feed-forward loop where synaptic energy failure leads to further transport impairment, accelerating synaptic loss [16](https://pubmed.ncbi.nlm.nih.gov/16751856/).

APOE ε4 Effects

APOE ε4, the major genetic risk factor for AD, impairs axonal transport through lipid metabolism disruption. APOE4 carriers show reduced transport efficiency even before clinical symptoms, suggesting that transport impairment may be an early biomarker and potentially a therapeutic target [17](https://pubmed.ncbi.nlm.nih.gov/24868089/). The mechanism involves altered lipid transport to neurons, affecting the lipid composition of membranes and thus motor protein function.

Parkinson's Disease

PD shows particularly severe mitochondrial transport defects. α-Synuclein aggregates bind to microtubules and motor proteins, disrupting transport efficiency. Mutations in LRRK2 affect microtubule dynamics and motor protein function. PINK1 and Parkin, involved in mitophagy, also regulate mitochondrial transport through Miro1 degradation. When mitophagy is impaired, damaged mitochondria accumulate in axons. Dopaminergic neurons are especially vulnerable due to their high energy demands and pacemaking activity. The combination of mitochondrial transport failure and protein aggregation leads to progressive axonal degeneration.

α-Synuclein Binding to Transport Machinery

α-Syn binds directly to tubulin and microtubules with high affinity, particularly when phosphorylated at Ser129 [18](https://pubmed.ncbi.nlm.nih.gov/23278949/). This binding can stabilize microtubules when monomeric, but oligomeric and fibrillar forms disrupt transport by multiple mechanisms:

• Lewy body formation traps transport machinery, preventing its recycling and function
• Oligomeric α-Syn inhibits kinesin function directly, reducing anterograde transport
• α-Syn oligomers bind to the lysosomal membrane, impairing fusion and retrograde transport
• Preformed fibrils (PFFs) impair lysosomal acidification and cathepsin activation [19](https://pubmed.ncbi.nlm.nih.gov/24934463/)

LRRK2 Effects on Transport

LRRK2 mutations (G2019S being most common) disrupt dynein function through multiple pathways. LRRK2 phosphorylates tubulin, affecting microtubule polymerization and stability. The kinase activity of LRRK2 also affects microtubule-based motors directly, altering their binding and processivity. Interestingly, LRRK2 can phosphorylate JIP3, a kinesin adaptor, disrupting its function and impairing axonal transport of multiple cargo types [21](https://pubmed.ncbi.nlm.nih.gov/21857689/).

PINK1/Parkin Pathway

The PINK1/Parkin pathway regulates both mitochondrial quality control and transport. Upon mitochondrial damage, PINK1 stabilizes on the outer mitochondrial membrane and phosphorylates ubiquitin and parkin, activating mitophagy. This pathway also regulates mitochondrial transport through Miro1 degradation—phosphorylation of Miro1 by PINK1 triggers its removal, halting transport of damaged mitochondria and enabling their autophagic clearance.

In PD, mutations in PINK1 and parkin (accounting for ~10% of familial PD) disrupt this pathway. The failure to properly tag and clear damaged mitochondria leads to accumulation of dysfunctional mitochondria in axons, further exacerbating energy deficits and oxidative stress. This creates a feed-forward cycle where impaired mitophagy leads to transport of healthy mitochondria being compromised by damaged organelles [22](https://pubmed.ncbi.nlm.nih.gov/23695683/).

Amyotrophic Lateral Sclerosis

ALS exhibits severe fast axonal transport defects affecting both anterograde and retrograde transport. TDP-43 pathology disrupts the transport machinery by altering RNA processing of motor protein components. Kinesin heavy chain expression is reduced in motor neurons. C9orf72 dipeptide repeats disrupt microtubule-based transport through toxic gain-of-function. SOD1 mutations cause direct impairment of fast axonal transport. The defect leads to accumulation of organelles and proteins in proximal axons, contributing to swelling and denervation at the neuromuscular junction.

Dynein/Dynactin Mutations and Dysfunction

DCTN1 mutations cause progressive motor neuron disease, demonstrating the critical importance of retrograde transport for motor neuron survival [23](https://pubmed.ncbi.nlm.nih.gov/16580966/). DCTN1 encodes the p150Glued subunit of dynactin, which is essential for dynein processivity and cargo binding. Mutations in DCTN1 cause Perry syndrome, a rare parkinsonian disorder, and can also cause ALS-like phenotypes.

DYNC1H1 mutations (the heavy chain of cytoplasmic dynein) impair retrograde transport and cause hereditary spastic paraplegia and Charcot-Marie-Tooth disease. In ALS, dynein function is compromised by multiple mechanisms beyond genetic mutations:

• TDP-43 pathology affects dynein expression and regulation
• SOD1 aggregates interfere with dynein function
• Energy deficits impair dynein ATPase activity [24](https://pubmed.ncbi.nlm.nih.gov/15282275/)

TDP-43 aggregation (present in 97% of ALS cases and 50% of FTD) disrupts microtubule organization and transport through multiple mechanisms [25](https://pubmed.ncbi.nlm.nih.gov/20805878/):

• Loss of nuclear TDP-43 affects transport protein expression (TDP-43 regulates splicing of many transport-related mRNAs)
• Cytoplasmic inclusions trap transport machinery
• TDP-43 directly interacts with microtubules and affects their stability
• ALS-causing mutations in TDP-43 enhance its aggregation and toxic effects

The C9orf72 hexanucleotide repeat expansion (most common genetic cause of familial ALS/FTD) produces toxic dipeptide repeat proteins (DPRs) that disrupt axonal transport:

• Poly-GA DPRs form inclusions that block transport
• Arginine-rich DPRs (poly-PR, poly-GR) interact with nucleoporins and transport machinery
• The loss-of-function of C9orf72 protein (which localizes to endosomal compartments) also affects transport [26](https://pubmed.ncbi.nlm.nih.gov/23891322/)

SOD1 mutations (20% of familial ALS) directly impair axonal transport through multiple mechanisms:

• Mutant SOD1 forms aggregates that trap transport proteins
• SOD1 aggregates block the axon, causing swellings
• Motor neurons are particularly vulnerable due to their extreme length and high transport demands
• Mitochondrial transport is specifically impaired, contributing to energy deficits [27](https://pubmed.ncbi.nlm.nih.gov/24791336/)

Neurofilament accumulation is a hallmark of ALS and contributes to transport defects:

• NF-L and NF-H aggregation blocks axonal transport
• Phosphorylation abnormalities affect NF assembly and transport
• Elevated NF in CSF is a key biomarker for disease progression
• The accumulation of neurofilament in proximal axons contributes to "ballooned" neurons seen in ALS

Frontotemporal Dementia

FTD shows axonal transport defects that vary by pathological subtype. In TDP-43 pathology, disrupted RNA processing affects expression of transport proteins. Tau pathology (FTDP-17) directly destabilizes microtubules, impairing all cargo transport. Progranulin deficiency affects lysosomal function, which indirectly impacts transport through impaired organelle turnover. Transport deficits in FTD correlate with the characteristic frontotemporal atrophy and behavioral changes.

Tau-Dependent Mechanisms

MAPT mutations (causing FTDP-17) disrupt microtubule binding through multiple mechanisms [28](https://pubmed.ncbi.nlm.nih.gov/10508520/):

• Mutations in the microtubule-binding repeat domains reduce tau-microtubule binding
• 3R/4R tau isoform imbalances affect transport differentially
• Tauopathies (Pick's disease, corticobasal degeneration, progressive supranuclear palsy) all impair transport

• Frontotemporal lobes are preferentially affected in FTD vs. hippocampus in AD
• Different tau isoform composition (3R4R in Pick's vs. 4R in PSP/CBD)
• Variable response to tau-targeting therapies

TDP-43 aggregation in FTD (approximately 50% of cases, called FTD-TDP) disrupts transport through [29](https://pubmed.ncbi.nlm.nih.gov/21129527/):

• RNA processing defects altering transport protein expression (TDP-43 regulates hundreds of mRNAs)
• Direct interaction with microtubules affecting their organization
• Cytoplasmic inclusions disrupting transport infrastructure
• Loss of nuclear function affecting gene expression needed for transport

FUS (fused in sarcoma) mutations cause a small percentage of FTD cases:

• FUS mutations affect transport regulation through RNA processing
• Nuclear import/export defects related to transport
• FUS localizes to stress granules, which can block transport when persistent [30](https://pubmed.ncbi.nlm.nih.gov/25655647/)

Progranulin mutations (10-20% of FTD) lead to haploinsufficiency:

• Progranulin is essential for lysosomal function
• GRN deficiency causes cathepsin D mislocalization
• Impaired lysosomal function affects organelle turnover and transport
• Microglial inflammation from GRN deficiency further impairs neuronal transport [31](https://pubmed.ncbi.nlm.nih.gov/23528757/)

Huntington's Disease

HD features impaired anterograde transport as a central pathological mechanism. Mutant huntingtin (mHtt) binds to kinesin-1 and impairs its ability to transport cargo along microtubules. mHtt also disrupts dynein function through altered protein interactions. Mitochondrial transport is severely impaired, causing energy deficits in distal axons. The microtubule-based transport defects contribute to synaptic dysfunction in striatal medium spiny neurons. Transcriptional dysregulation by mHtt reduces expression of transport-related proteins.

Huntingtin Cargo Function

Wild-type HTT acts as a scaffold for transport proteins, binding to kinesin, dynein, and various adaptors [32](https://pubmed.ncbi.nlm.nih.gov/11821364/). This scaffolding function is lost in mutant HTT:

• Mutant HTT loses cargo adaptor function
• Polyglutamine expansion disrupts protein interactions
• mHTT can sequester wild-type HTT, causing a loss-of-function effect
• The interaction between HTT and JIP3 is impaired, affecting stress signaling and transport

Mutant HTT directly inhibits kinesin function through multiple mechanisms [33](https://pubmed.ncbi.nlm.nih.gov/14593171/):

• mHTT binds to the heavy chain of kinesin-1, reducing its processivity
• mHTT aggregation traps kinesin motors, preventing their function
• Dynein complex assembly is impaired by mutant HTT
• Both anterograde and retrograde transport are affected

Specific Cargo Deficits

Mitochondrial transport is severely impaired in HD, contributing to the energy deficits seen in striatal neurons:

• Miro1 function is altered by mutant HTT
• Mitochondrial dynamics (fusion/fission) are disrupted, affecting transport
• Energy deficits in distal processes lead to synaptic dysfunction
• Synaptic vesicle transport is reduced, contributing to neurotransmission defects
• Neurotrophic factor delivery (BDNF) is compromised due to transport defects [35](https://pubmed.ncbi.nlm.nih.gov/20069549/)

Mutant huntingtin causes widespread transcriptional dysregulation that affects transport proteins:

• Reduced expression of kinesin and dynein subunits
• Altered expression of microtubule-associated proteins
• Impaired transcription of mitochondrial dynamics proteins
• The net effect is a multi-level impairment of axonal transport

Mermaid Diagram: Axonal Transport Dysfunction Pathways

Protein Alterations Comparison

| Protein | AD | PD | ALS | FTD | HD | Function |
|---------|-----|-----|-----|-----|-----|----------|
| Kinesin-1 | ↓↓ | ↓↓ | ↓ | ↓ | ↓↓ | Anterograde transport |
| Kinesin-2 | ↓ | ↓ | - | - | ↓ | Anterograde transport |
| Dynein | ↓ | ↓ | ↓↓ | Variable | ↓ | Retrograde transport |
| Dynactin | ↓ | ↓ | ↓↓ | - | ↓↓ | Dynein activator |
| MAP2 | ↓↓ | - | - | ↓ | ↓ | Dendritic transport |
| Tau | ↑↑ (p-tau) | - | - | ↑ (p-tau) | - | MT stabilization |
| α-Synuclein | - | ↑↑ | - | - | - | MT binding |
| TDP-43 | - | - | agg | agg | - | RNA processing |
| Neurofilament-L | ↑ | - | agg/↑ | Variable | ↑ | Structure |
| Huntingtin | - | - | - | - | mut | Transport scaffold |

Diagnostic Biomarkers

CSF Biomarkers for Axonal Transport Defects

| Marker | AD | PD | ALS | FTD | HD | Interpretation |
|--------|-----|-----|-----|-----|-----|----------------|
| NfL (CSF) | ↑ | ↑ | ↑↑ | ↑ | ↑ | Axonal degeneration |
| p-NfH (CSF) | - | - | ↑↑ | - | ↑ | Phosphorylated NF |
| Tau (total) | ↑↑ | - | - | ↑ | - | Axonal damage |
| p-Tau181 | ↑↑ | - | - | ↑ | - | Tau pathology |
| α-Syn (CSF) | - | ↓ | - | - | - | Synuclein pathology |

Clinical Correlation

• AD: Transport defects correlate with cognitive decline; NfL predicts progression
• PD: Axonal transport markers correlate with motor progression; smell loss early marker
• ALS: NfL strongly predicts disease progression; earliest biomarker
• FTD: Biomarker profiles vary by subtype (tau vs TDP-43)
• HD: NfL correlates with disease progression and motor symptoms

Therapeutic Implications

Current Approaches

| Approach | Disease | Mechanism | Status |
|----------|---------|-----------|--------|
| Microtubule stabilizers | AD, HD | Enhance transport | Preclinical/clinical trials |
| LRRK2 inhibitors | PD | Restore microtubule function | Clinical trials |
| Mitochondrial agents | PD, AD, ALS | Improve energy supply | Various stages |
| Autophagy enhancers | PD, ALS, HD | Clear transport blockages | Preclinical |

| Strategy | Target | Disease | Stage |
|----------|--------|---------|-------|
| Microtubule stabilizers | Microtubules | AD, PD | Clinical trials |
| Kinesin activators | Kinesin function | PD, HD | Preclinical |
| Dynactin restoration | Dynein/dynactin | ALS | Gene therapy |
| HDAC6 inhibition | Tubulin acetylation | AD, PD, HD | Preclinical |
| Tau reduction | Tau pathology | AD, FTD | Clinical trials |

| Disease | Therapeutic Target | Approach |
|---------|-------------------|----------|
| AD | Microtubule stabilization | Tau-targeting drugs, microtubule-stabilizing compounds |
| PD | Motor protein function, energy | Mitochondrial protectors, α-syn aggregation inhibitors |
| ALS | KIF5A, transport machinery | Gene therapy for transport proteins, mitochondrial support |
| FTD | Transport restoration | Depends on subtype - tau or TDP-43 targeting |
| HD | Htt function restoration | Htt-lowering therapies, transport-enhancing compounds |

Emerging Strategies

• Gene therapy: Deliver functional motor proteins
• Small molecule modulators: Activate dormant transport machinery
• Antisense oligonucleotides: Reduce pathological protein expression
• Microtubule-stabilizing peptides: Deliver functional stabilization
• Autophagy enhancement: Clear transport-blocking aggregates

References

Axonal Transport in Alzheimer's Disease

Axonal Transport in Parkinson's Disease

Axonal Transport in ALS

Axonal Transport in FTD

Axonal Transport in Huntington's Disease

General Axonal Transport Mechanisms

Disease-Specific Pages

For detailed information on each disease, see:

• [Alzheimer's Disease - Synaptic Dysfunction](/mechanisms/synaptic-dysfunction) - Related: synaptic consequences of transport deficits
• [Parkinson's Disease - Protein Aggregation](/mechanisms/protein-aggregation) - Related: α-syn transport and aggregation
• [ALS - Synaptic Dysfunction](/mechanisms/synaptic-dysfunction) - Related: transport and neuromuscular junction
• [FTD - Protein Aggregation](/mechanisms/protein-aggregation) - Related: TDP-43 and tau
• [Huntington's Disease - Synaptic Dysfunction](/mechanisms/synaptic-dysfunction) - Related: striatal synaptic deficits

Cross-Links

• [Synaptic Dysfunction Comparison](/mechanisms/synaptic-dysfunction-comparison) - Related: synaptic consequences of transport failure
• [Protein Aggregation Comparison](/mechanisms/protein-aggregation-comparison) - Related: protein aggregates blocking transport
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) - Energy failure from transport defects
• [Autophagy Failure Comparison](/mechanisms/autophagy-failure-comparison) - Related: transport of autophagosomes
• [Cytoskeleton Dysfunction Comparison](/mechanisms/cytoskeleton-dysfunction-comparison) - Related: microtubule integrity

See Also

Related Hypotheses:

• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypotheses/h-856feb98)
• [Vagal Afferent Microbial Signal Modulation](/hypotheses/h-ee1df336)
• [Targeted APOE4-to-APOE3 Base Editing Therapy](/hypotheses/h-a20e0cbb)
• [APOE4 Allosteric Rescue via Small Molecule Chaperones](/hypotheses/h-44195347)
• [Selective APOE4 Degradation via Proteolysis Targeting Chimeras (PROTACs)](/hypotheses/h-11795af0)

• [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010)
• [RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1)

• [ER-Golgi Secretory Pathway Dysfunction in PD - Experiment Design](/experiment/exp-wiki-experiments-er-golgi-secretory-pathway-parkinsons)
• [Cytochrome Therapeutics](/experiment/exp-wiki-experiments-lipid-droplet-lysosome-axis-parkinsons)
• [LRRK2/GBA Mutation Carrier Resilience — Why Some Carriers Never Develop PD](/experiment/exp-wiki-experiments-lrrk2-gba-carrier-resilience-pd)